Enrollment is complete and testing underway in a Phase 1b/2 clinical trial of Vaccinex’s experimental therapy pepinemab, which aims…
Articles by Marisa Horak, MS
Eli Lilly’s anti-amyloid therapy donanemab significantly slowed cognitive decline for most people with early Alzheimer’s disease in the…
On-demand treatment with BXCL501, an orally dissolving film formulation of dexmedetomidine, significantly eased episodes of agitation among Alzheimer’s disease…
In the earliest stages of Alzheimer’s disease, even before cognitive symptoms have become apparent, there are detectable changes…
A blood test that checks for the abnormal activation of star-shaped cells in the brain called astrocytes may be able…
Eisai and Biogen are seeking approval in Canada and the U.K. for lecanemab to treat early…
Donanemab significantly slowed the decline of cognitive and functional abilities in people with early Alzheimer’s disease, according to top-line…
The U.S. Food and Drug Administration (FDA) has approved Rexulti (brexpiprazole) to treat agitation associated with dementia due to…
Eli Lilly’s donanemab was found to work better than Aduhelm (aducanumab) in a biomarker study of people with…
Treatment with the experimental therapy BIIB080 led to long-term reductions in the levels of disease-associated tau protein in the brains…